Search

International audience; BACKGROUND: We recently identified a facilitory control exerted by serotonin4 (5-HT4) receptors on the in vivo firing activity of dorsal raphe nucleus (DRN) serotonergic (5-HT) neurons. However, these findings were based on acute administrations of 5-HT4 receptor agonists and antagonists, which were active only in a subpopulation of 5-HT neurons. We had no evidence that this influence was significant when considering the entire DRN, nor if it was persistent after chronic treatments. In addition, the poor distribution of 5-HT4 receptors within the DRN raised the question of the neuroanatomical bases underlying this control. METHODS AND RESULTS: Here we show that the subacute intraperitoneal (IP) injection of the 5-HT4 receptor agonists prucalopride (2.5 mg/kg) and RS 67333 (1.5 mg/kg) 30 minutes before the beginning of recordings augment the mean firing rate of DRN neurons by 40% and 66%, respectively. These increases remain stable when the compounds are administered continuously during 3 and 21 days; the effects of the 3-day treatment are blocked by the 5-HT4 receptor antagonist GR 125487 (1000 microg/kg, intravenous [i.v.]). In addition, stereotaxic microinjections of herpes simplex viruses, transformed to overexpress 5-HT4 receptors, increase DRN 5-HT neuronal mean activity when performed in the medial prefrontal cortex (mPFC) but not in the striatum or in the hippocampus. CONCLUSIONS: This finding suggests the existence of a 5-HT(4)-dependent activation of DRN that may involve the mPFC, unveiling the 5-HT4 receptor as a putative player in the physiopathology of several disorders related to central 5-HT dysfunction.

Inhibitory synaptic transmission in the dorsal horn (DH) of the spinal cord plays an important role in the modulation of nociceptive messages because pharmacological blockade of spinal GABAAreceptors leads to thermal and mechanical pain symptoms. Here, we show that during the development of thermal hyperalgesia and mechanical allodynia associated with inflammatory pain, synaptic inhibition mediated by GABAAreceptors in lamina II of the DH was in fact markedly increased. This phenomenon was accompanied by an upregulation of the endogenous production of 5α-reduced neurosteroids, which, at the spinal level, led to a prolongation of GABAAreceptor-mediated synaptic currents and to the appearance of a mixed GABA/glycine cotransmission. This increased inhibition was correlated with a selective limitation of the inflammation-induced thermal hyperalgesia, whereas mechanical allodynia remained unaffected. Our results show that peripheral inflammation activates an endogenous neurosteroid-based antinociceptive control, which discriminates between thermal and mechanical hyperalgesia.

International audience; Brain-derived neurotrophic factor (BDNF) regulates neuronal development and function. However, it has been difficult to discern its role in the adult brain in influencing complex behavior. Here, we use a recently developed inducible knockout system to show that deleting BDNF in broad forebrain regions of adult mice impairs hippocampal-dependent learning and long-term potentiation. We use the inducible nature of this system to show that the loss of BDNF during earlier stages of development causes hyperactivity and more pronounced hippocampal-dependent learning deficits. We also demonstrate that the loss of forebrain BDNF attenuates the actions of desipramine, an antidepressant, in the forced swim test, suggesting the involvement of BDNF in antidepressant efficacy. These results establish roles for BDNF in the adult, and demonstrate the strength of this inducible knockout system in studying gene function in the adult brain.

Neurotrophic factor signaling pathways modulate cellular and behavioral responses to drugs of abuse. In addition, chronic exposure to morphine increases expression of phospholipase Cgamma1 (PLCgamma1) (a protein involved in neurotrophic signaling) in the ventral tegmental area (VTA), a neural substrate for many drugs of abuse. Using viral-mediated gene transfer to locally alter the activity of PLCgamma1, we show that overexpression of PLCgamma1 in rostral portions of the VTA (R-VTA) results in increased morphine place preference, whereas PLCgamma1 overexpression in the caudal VTA (C-VTA) results in avoidance of morphine-paired compartments. In addition, overexpression of PLCgamma1 in R-VTA causes increased preference for sucrose and increased anxiety-like behavior but does not affect responses to stress or nociceptive stimuli. In contrast, overexpression of PLCgamma1 in C-VTA decreases preference for sucrose and increases sensitivity to stress and nociceptive stimuli, although there was a tendency for increased anxiety-like behavior as seen for the R-VTA. These results show that levels of PLCgamma1 in the VTA regulate responsiveness to drugs of abuse, natural rewards, and aversive stimuli and point to the possibility that distinct topographical regions within the VTA mediate generally positive versus negative responses to emotional stimuli. Moreover, these data also support a role for drug-induced elevations in PLCgamma1 expression in the VTA in mediating long-term adaptations to drugs of abuse and aversive stimuli.

Administration of cocaine induces the Fos family of transcription factors in the striatum, including the nucleus accumbens (NAc), a brain region important for the rewarding effects of addictive drugs. Several Fos proteins are induced acutely by cocaine, with stable isoforms of DeltaFosB predominating after chronic drug administration. However, it has been difficult to study the functional consequences of these Fos responses in vivo. Fos proteins heterodimerize with members of the Jun family to form active AP-1 transcription factor complexes. In the present study, we took advantage of this property and generated transgenic mice, using the tetracycline gene regulation system, that support the inducible, brain region-specific expression of a dominant negative mutant form of c-Jun (Deltac-Jun), which can antagonize the actions of Fos proteins. Expression of Deltac-Jun in the striatum and certain other brain regions of adult mice decreases their development of cocaine-induced conditioned place preference, suggesting reduced sensitivity to the rewarding effects of cocaine. In contrast, Deltac-Jun expression had no effect on cocaine-induced locomotor activity or sensitization. However, expression of Deltac-Jun in adult mice blocked the ability of chronic cocaine administration to induce three known targets for AP-1 in the NAc: the AMPA glutamate receptor subunit GluR2, the cyclin-dependent protein kinase Cdk5, and the transcription factor nuclear factor-kappaB (NFkappaB), without affecting several other proteins examined for comparison. Taken together, these results provide further support for an important role of AP-1-mediated transcription in some of the behavioral and molecular mechanisms underlying cocaine addiction.

The lateral hypothalamus (LH) is implicated in the behavioral actions of drugs of abuse, but the cellular and molecular basis of this role is unclear. Recent identification of neuropeptides localized in LH neurons has allowed for more specific studies of LH function. The LH-specific peptide orexin (hypocretin) has been shown to be important in arousal and sleep regulation. However, orexin cells of the LH project broadly throughout the brain such that orexin may influence other behaviors as well. In this study, we show that orexin neurons, and not nearby LH neurons expressing melanin-concentrating hormone (MCH), have mu-opioid receptors and respond to chronic morphine administration and opiate antagonist-precipitated morphine withdrawal. cAMP response element-mediated transcription is induced in a subset of orexin cells, but not MCH cells, after exposure to chronic morphine or induction of withdrawal. Additionally, c-Fos and the orexin gene itself are induced in orexin cells in the LH during morphine withdrawal. Finally, we show that orexin knock-out mice develop attenuated morphine dependence, as indicated by a less severe antagonist-precipitated withdrawal syndrome. Together, these studies support a role for the orexin system in molecular adaptations to morphine, and demonstrate dramatic differences in molecular responses among different populations of LH neurons.

Chronic opiate exposure is associated with upregulation of the cAMP signaling pathway and the transcription factor cAMP response element-binding protein in the locus ceruleus (LC) and certain other brain areas. To determine whether these adaptations ultimately affect transcription mediated by the cAMP response element (CRE), we induced morphine dependence in CRE-LacZ transgenic mice and performed a regional and cellular mapping of beta-galactosidase (beta-gal) expression during naltrexone-precipitated withdrawal. Consistent with our model of opiate dependence, beta-gal expression increased in the LC, but decreased in the lateral ventral tegmental area (VTA) and dorsal raphe nucleus (DRN). In addition, withdrawal increased beta-gal expression in the continuum of the extended amygdala and nucleus accumbens, macrostructures associated with the coupling of emotional stimuli to motor and autonomic responses. At the cellular level, in the central nucleus of the amygdala, beta-gal was found in cells both with and without mu opioid receptors as well as in corticotropin-releasing factor-expressing cells. In nucleus accumbens, beta-gal was expressed in several major subpopulations of neurons. In LC, beta-gal expression was induced predominantly in tyrosine hydroxylase-expressing cells, whereas in the VTA and DRN the majority of cells expressing beta-gal were nonmonoaminergic. These results show that molecular adaptations to chronic morphine alter CRE-mediated transcription during opiate withdrawal in physiologically salient regions involved in arousal, reward, mood, and affective responses. We propose that CRE-mediated transcription serves as a functional marker for neuronal plasticity during withdrawal. CRE-mediated transcription may itself contribute to re-establishing homeostasis in the organism through target gene regulation in these regions.

Comment on : Opioid facilitation of rewarding electrical brain stimulation is suppressed in rats with neuropathic pain. [Anesthesiology. 2011]

The calcium-binding protein calbindin-D28K is an anatomical marker that has been associated with resistance to neurodegeneration and with the electrophysiological characteristics of neurons. In this study, we compared the presence of calbindin in dopamine neurons projecting to three distinct functional regions of the striatal complex: the striatum, and the core and the shell of the nucleus accumbens. After iontophoretic injections of Fluoro-Gold in the dopaminergic terminal fields, the presence of tyrosine hydroxylase and calbindin were immunohistochemically assessed in the mesencephalon. It was found that the proportion of cells expressing calbindin was highest in the dopamine cells projecting to the core (72%), intermediate in the cells projecting to the shell (51%) and lowest in the cells projecting to the dorsolateral striatum (2.6%). These results do not support the idea that calbindin is a sufficient condition to confer resistance to neurodegeneration because shell-projecting neurons seem the most resistant to it. The present data also raise the question of the role of calbindin in the differences in firing characteristics among dopamine neurons projecting to the striatal complex.

Recent work implicates regulation of neurogenesis as a form of plasticity in the adult rat hippocampus. Given the known effects of opiates such as morphine and heroin on hippocampal function, we examined opiate regulation of neurogenesis in this brain region. Chronic administration of morphine decreased neurogenesis by 42% in the adult rat hippocampal granule cell layer. A similar effect was seen in rats after chronic self-administration of heroin. Opiate regulation of neurogenesis was not mediated by changes in circulating levels of glucocorticoids, because similar effects were seen in rats that received adrenalectomy and corticosterone replacement. These findings suggest that opiate regulation of neurogenesis in the adult rat hippocampus may be one mechanism by which drug exposure influences hippocampal function.

We analyzed the influence of the transcription factor DeltaFosB on learned helplessness, an animal model of affective disorder wherein a subset of mice exposed to inescapable stress (IS) develop a deficit in escape behavior. Repeated IS induces DeltaFosB in the ventrolateral periaqueductal gray (vlPAG), and levels of the protein are highly predictive of an individual's subsequent behavorial deficit-with the strongest DeltaFosB induction observed in the most resilient animals. Induction of DeltaFosB by IS predominates in substance P-positive neurons in the vlPAG, and the substance P gene, a direct target for DeltaFosB, is downregulated upon DeltaFosB induction. Local overexpression of DeltaFosB in the vlPAG using viral-mediated gene transfer dramatically reduces depression-like behaviors and inhibits stress-induced release of substance P. These results indicate that IS-induced accumulation of DeltaFosB in the vlPAG desensitizes substance P neurons enriched in this area and opposes behavioral despair by promoting active defense responses.

The active zone protein RIM1alpha is required both for maintaining normal probability of neurotransmitter release and for long-term presynaptic potentiation at brain synapses. We now demonstrate that RIM1alpha(-/-) mice exhibit normal coordination and anxiety-related behaviors but display severely impaired learning and memory. Mice with a synaptotagmin 1 mutation, which selectively lowers release probability, and mice with Rab3A deletion, which selectively abolishes presynaptic long-term potentiation, do not exhibit this abnormality. Our data suggest that a decrease in release probability or a loss of presynaptic LTP alone is not sufficient to cause major behavioral alterations, but the combination of presynaptic abnormalities in RIM1alpha(-/-) mice severely alters learning and memory.

Neuropathic pain is a health issue in aging countries such as France. Indeed, it has a significant impact on patients' quality of life, both privately and professionally. Nowadays, first-line treatments are antiepileptics or antidepressants, notably amitriptyline. However, these treatments, which may take a long time to treat, are not systematically effective and may have disabling side effects. Therefore, the research aims to better understand the mechanisms of neuropathic pain and the mechanisms of action of its treatment. Several animal studies have shown glial remodeling during neuropathies involving gap junctions. However, the modulation of their transmembrane proteins has shown beneficial effects on painful symptoms in many models. Also, co-administration of amitriptyline and mefloquine (glial modulator) significantly improves the effects induced by amitriptyline alone, in vitro, or in vivo. The goal of this thesis was to determine the mechanisms of action of this combination in a preclinical model., Les douleurs neuropathiques représentent un enjeu de santé dans les pays vieillissants comme la France. En effet, leur survenue impacte significativement la qualité de vie des patients, sur les plans privé et professionnel. De nos jours, la prise en charge médicale de ces douleurs se fait en première intention avec des antiépileptiques ou des antidépresseurs, dont l’amitriptyline. Néanmoins, ces traitements, dont le délai thérapeutique peut être long, ne sont pas systématiquement efficaces ou entrainent des effets indésirables parfois invalidants. Par conséquent, les recherches visent à mieux connaître la physiopathologie des douleurs neuropathiques et les mécanismes d’action de leurs traitements. Un certain nombre d’études chez l’animal ont mis en évidence un remodelage glial lors de la mise en place des neuropathies, impliquant les jonctions communicantes. Or, la modulation des protéines transmembranaires qui les composent a montré des effets bénéfiques sur les symptômes douloureux dans de nombreux modèles. Aussi, la co-administration d’amitriptyline et de méfloquine (modulateur glial) permet d’améliorer significativement les effets induits par le traitement de référence seul, dans des modèles in vitro ou in vivo. L’objectif de cette thèse a été d’en déterminer les mécanismes d’action dans un modèle préclinique.

The tail of the ventral tegmental area (tVTA) is the major brake of the midbrain dopamine neurons. This structure although studied, is not yet referenced in stereotaxic atlases. Anatomically, this work allowed to obtain a reference definition of the tVTA through its neurochemical, stereological, connectivity-based and genomic analyses. Functionally, we studied its role for the response of aversive stimuli and we tested its influence on motor and non-motor symptoms of Parkinson’s disease. We observed that a co-lesion of the tVTA in a rodent model of the disease induce motor, nociceptive and depressive-like symptoms improvements. This work has thus contributed to the progress of our knowledge on the tVTA and opens new explorative track for its functional implication., La queue de l’aire tegmentale ventrale (tVTA) est le principal contrôle inhibiteur des neurones dopaminergiques du mésencéphale. Cette structure, bien qu’aujourd’hui très étudiée, n’est cependant pas encore référencée dans les atlas stéréotaxiques. Anatomiquement, nous avons pu apporter une définition de référence de la tVTA, à travers son analyse neurochimique, stéréologique, hodologique et génomique. Fonctionnellement, nous avons montré son rôle dans la réponse à des expériences émotionnelles aversives et nous avons testé son influence sur les symptômes moteurs et non-moteurs de la maladie de Parkinson. Nous avons ainsi montré qu’une co-lésion de la tVTA dans un modèle murin de la maladie permet une amélioration des performances motrices, des seuils nociceptifs et des symptômes de type dépressifs. Ce travail a ainsi participé au progrès de nos connaissances sur la tVTA et ouvre de nouvelles pistes d’exploration quant à son implication fonctionnelle.

Neuropathic pain is caused by a lesion or a disease of the somatosensory nervous system. Pregabalin, an anticonvulsant, and duloxetine, an antidepressant, are the standard treatments, effective in one-third of patients. A better understanding of their mechanisms of action is a crucial point to improve their tolerance and efficiency. By using a murine model of peripheral neuropathy, we have shown that : 1) pregabalin, whose effect is independent from the opioid system, acts on the peripheral neuroimmune component of pain ; 2) duloxetine acts via two independent mechanisms, one central (descending controls) for an acute treatment and the other peripheral (dorsal root ganglia) for a chronic treatment. In this case, transcriptomic analysis hightlights an inhibition of the neurogenic inflammation. Comparison of duloxetine plasmatic levels in humans and mice suggests a peripheral action in humans., La douleur neuropathique est due à une lésion ou une pathologie du système nerveux somatosensoriel. La prégabaline, un anticonvulsivant, et la duloxétine, un antidépresseur, sont des traitements de référence, efficaces chez un tiers des patients. Mieux comprendre leurs mécanismes d’action est crucial pour améliorer leur tolérance et leur efficacité. En utilisant un modèle murin de douleur neuropathique périphérique, nous montrons que : 1) la prégabaline, dont l’action est indépendante du système opioïdergique, agit sur la composante neuroimmunitaire périphérique de la douleur ; 2) la duloxétine agit via deux mécanismes indépendants, l’un central (contrôles descendants) pour un traitement aigu et l’autre périphérique (ganglion rachidien) pour un traitement chronique. Dans ce cas, l’analyse transcriptomique met en évidence une inhibition de l’inflammation neurogène. La comparaison des taux plasmatiques de duloxétine chez l’homme et chez la souris suggère une action périphérique chez l’homme.

The tail of the ventral tegmenta area (tVTA) is a GABAergic brain region located behind the VTA. It projects massively to dopaminergic neurons in mesencephalic A9 and A10 groups leading to nigrostriatal and mesolimbic systems that play a role in fonctions like motricity and drug-related behaviours. The objective of my thesis is to study the tVTA role through its projections to these systems. For that, we used various approaches including immunohistochemistry, in vivo pharmacology, in vivo electrophysiology, and motor behaviour. Between various drugs belonging to different classes, molecular activation of the tVTA by FosB/ΔFosB induction is only observed following psychostimulant treatment and is mediated by dopamine. From a physiological point of view, the tVTA exerts an inhibitory tone onto VTA dopamine neurons and plays a crucial role in morphine-induced desinhibition. Finally, tVTA lesions modulate nigrostriatal system mediated behaviour like amphetamine-induced rotational behaviour, motor coordination and motor skill learning., La queue de l'aire tegmentale ventrale (tVTA) est une région cérébrale GABAergique localisée en arrière de la VTA. Elle projette de façon massive aux neurones dopaminergiques des groupes A9 et A10 du mésencéphale à l'origine des systèmes nigrostrié et mésolimbique. Ces systèmes sont impliqués dans de nombreuses fonctions comme la motricité et les comportements associés aux drogues. L'objectif de ma thèse est d'étudier le rôle de la tVTA via ses projections sur ces systèmes. Pour cela, nous avons utilisé des approches variées comprenant l'immunohistochimie, la pharmacologie in vivo,l'électrophysiologie in vivo et l'étude du comportement moteur. Parmi un ensemble de drogues appartenant à différentes classes, l'activation moléculaire de la tVTA sous forme de l'induction de FosB/ΔFosB est spécifique des psychostimulants et dépend de la dopamine. D'un point de vue physiologique, la tVTA exerce un tonus inhibiteur sur les neurones dopaminergiques de la VTA et joue un rôle crucial dans leur désinhibition par la morphine. Enfin, des lésions de la tVTA influencent des comportements dépendant du système nigrostrié comme le comportement de rotation provoqué par l'amphétamine, les performances motrices et l'apprentissage moteur.

Antidepressants have an antiallodynic action that is dependent on β2-adrenoceptor stimulation. These receptors stimulate the cAMP production, which is regulated by type 4 phosphodiesterases (PDE4). Here, we studied that action of PDE inhibitors (iPDE) on neuropathic pain, using behavioral pharmacology approaches in mice, completed by calcium imaging and molecular approaches. Our results show the iPDE4s and iPDE5s have an antiallodynic action. The iPDE4s act through a decreased expression of TNFα in dorsal root ganglia and the recruitment of the delta opioid receptors. The action of iPDE5 requires both mu and delta opioid receptors. We also show that the action of an iPDE4 depends on the dose, the activation of glial cells at low dose being correlated with an antiallodynic action, while the recruitment of neurons at higher doses has a pronociceptive action via TRPV1 receptors.; Les antidépresseurs ont un effet antiallodynique qui dépend de la stimulation des récepteurs β2-adrénergiques. Ceux-ci stimulent la production d’adénosine monophosphate cyclique (AMPc) régulé par les phosphodiestérases de type 4 (PDE4). Nous avons ici étudié l’effet d’inhibiteurs de PDE (iPDE) sur la douleur neuropathique, grâce à des approches de pharmacologie comportementale chez la souris complétées par de l’imagerie calcium et des approches moléculaires. Nos résultats montrent un effet antiallodynique des iPDE4 et des iPDE5. L’action des iPDE4 est liée à une diminution d’expression du TNFα dans le ganglion rachidien et au recrutement des récepteurs delta des opioïdes. Celle des iPDE5 nécessite à la fois les récepteurs mu et delta. Nous montrons aussi que l’action d’un iPDE4 dépend de la dose, l’activation de cellules gliales semblant corrélée à l’effet antiallodynique à faible dose, alors que celle des neurones à forte dose a un effet pronociceptif via les récepteurs TRPV1.

Neuropathic pain is caused by a lesion or disease of the somatosensory nervous system and is badly relieved by usual antalgics. In our preclinical work, we studied the effect of various molecules, in particular antidepressant and anticonvulsant drugs wich are recommended in the treatment of neuropathic pain. In a murine model of traumatic neuropathy, we studied the influence of the period of treatment, early or late, on the mechanical allodynia. An early treatment with gabapentin or carbamazepine leads to a preventive effect on sustained allodynia. In a murine model of diabetic neuropathy, we characterized the antiallodynic action of nortriptyline and terbutaline. In our clinical work, we realized a retrospective survey on patients operated by thoracotomy. The analysis of the results show a significant decrease of the risk to suffer from chronic pain with neuropathic characteristics in patients treated with long-term β2- agonists.; Les douleurs neuropathiques sont secondaires à une maladie ou à une lésion affectant le système nerveux somatosensoriel et sont mal soulagées par les antalgiques usuels. Dans notre travail préclinique, nous avons étudié l’effet de différentes molécules, dont des antidépresseurs et antiépileptiques recommandés dans le traitement des douleurs neuropathiques. Dans un modèle murin de neuropathie traumatique, nous avons étudié l’influence de la période de traitement, précoce ou tardif, sur l’allodynie mécanique. Un traitement précoce par gabapentine ou par carbamazépine permet d’observer un effet préventif sur la chronicisation de l’allodynie. Dans un modèle murin de neuropathie diabétique, nous avons caractérisé l’action anti-allodynique d’un traitement par nortriptyline et par terbutaline. En clinique, nous avons réalisé un travail d’enquête rétrospective sur des patients opérés par thoracotomie. L’analyse des résultats montre une diminution significative du risque de présenter des douleurs chroniques avec des caractéristiques neuropathiques chez les patients traités par β2-agonistes au long cours.

Neuropathic pain is defined as a pain caused by a lesion or disease of the somatosensory nervous system. Around 30% of neuropathic pain patients develop mood disorders. The biologic bases of these comorbidities are not clearly established. Using a murine model of neuropathic pain, we tried to understand the emotional consequences of neuropathic pain. Thus, we identified cerebral regions involved in the different components of pain and molecular modifications taking place in these regions. We showed a cortical separation of the pain experience with on one hand the integration of the sensory component of pain in the posterior insular cortex and on the other hand the integration of the aversive component and the emotional consequences of pain in the anterior cingulate cortex (ACC). Looking at the molecular modifications in the ACC, we showed that MKP-1, a protein able to dephosphorylate the MAPK, is involved in the development of pain-related mood disorders in our model of neuropathic pain., La douleur neuropathique est un syndrome secondaire à une maladie ou à une lésion affectant le système nerveux somatosensoriel. Environ 30% des patients souffrant de douleurs neuropathiques présentent des troubles de l’humeur. Les causes biologiques de ces comorbidités ne sont pas clairement établies. Grâce à l’utilisation d’un modèle murin de douleur neuropathique, nous avons cherché à comprendre l’apparition des conséquences émotionnelles de cette douleur. Pour cela, nous avons cherché à identifier des régions cérébrales impliquées dans les différentes composantes et conséquences de la douleur ainsi que les modifications moléculaires y prenant place. Nous avons mis en évidence une ségrégation corticale de la douleur avec l’intégration de la composante sensorielle par le cortex insulaire postérieur d’une part et l’intégration de la composante aversive et des conséquences émotionnelles par le cortex cingulaire antérieur d’autre part. Nous avons ensuite montré l’implication de la protéine MKP-1 dans l’expression des comportements de type anxiodépressif dans notre modèle.